These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33597868)

  • 1. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Zheng Q; Wang Y; Yang H; Sun L; Fu X; Wei R; Liu YN; Liu WJ
    Front Pharmacol; 2020; 11():573645. PubMed ID: 33597868
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
    Fu Z; Geng X; Chi K; Song C; Wu D; Liu C; Hong Q
    Front Pharmacol; 2022; 13():746265. PubMed ID: 35359863
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.
    Fatima K; Ahmed W; Fatimi AS; Mahmud O; Mahar MU; Ali A; Aamir SR; Nasim MT; Islam MB; Maniya MT; Azim D; Marsia S; Almas T
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1867-1875. PubMed ID: 36195739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis.
    Huang Q; Liao Z; Liu X; Xia Y; Wang J
    Int Urol Nephrol; 2023 Feb; 55(2):325-334. PubMed ID: 35960479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
    Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
    Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
    Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
    Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.
    Ali Fadlalmola H; Al-Sayaghi KM; Al-Hebshi AA; Alhujaily M; Alyamani AO; Alem AA; Syrafi MH; Alem S; Farhat AH; Mohamed FA; Abdalrahman HH; Abdelmalik MA; Abdalrhman NM; Eltayeb AM
    Pan Afr Med J; 2024; 47():114. PubMed ID: 38828426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
    Fadlalmola H; Al-Sayaghi K; Al-Hebshi A; Aljohani M; Albalawi M; Kashari O; Alem A; Alrasheedy M; Balelah S; Almuteri F; Alyamani A; Alwasaidi T
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
    Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
    Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
    [No Abstract]   [Full Text] [Related]  

  • 10. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
    Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
    BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.
    Holdstock L; Cizman B; Meadowcroft AM; Biswas N; Johnson BM; Jones D; Kim SG; Zeig S; Lepore JJ; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):129-138. PubMed ID: 30746140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of molidustat for anemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
    Kang Y; Zhou M; Jin Q; Geng YL; Wang Y; Lv J
    Heliyon; 2024 May; 10(9):e30621. PubMed ID: 38765138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.
    Xie D; Wang J; Wu X; Li M
    Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Malik B; Savarapu P; Eltobgy M; Kunadi A
    PLoS One; 2022; 17(4):e0266243. PubMed ID: 35363823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials.
    Abdelazeem B; Abbas KS; Shehata J; El-Shahat NA; Baral N; Savarapu P; Kunadi A
    Ann Transl Med; 2021 Dec; 9(23):1714. PubMed ID: 35071408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
    Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
    Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
    Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
    Jia L; Dong X; Yang J; Jia R; Zhang H
    Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
    Meadowcroft AM; Cizman B; Holdstock L; Biswas N; Johnson BM; Jones D; Nossuli AK; Lepore JJ; Aarup M; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):139-148. PubMed ID: 30746141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.